The current invention provides an improved method for more precise prognosis of patients having acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). The combination of performing a platelet function test prior to PCI and measuring Heart Fatty Acid Binding Protein (H-FABP) prior to PCI can more precisely risk-stratify the patients and has the potential to allow selection of patients who may benefit from more intense platelet inhibition.
展开▼
